Question explored with the scientific record
Why is Ajovy available only in 225mg syringes? Why is there no 175mg, for example? How did the drug manufacturer arrive at that dose and can I see that data? What dose ranges did they test?
The short version: the 225 mg dose was chosen from phase 2/3 trials that tested a few fixed doses, not a full dose-ranging study, and the evidence for that specific number is thin in the records retrieved.
The HALO trial for chronic migraine tested two fremanezumab regimens: 225 mg monthly and 675 mg quarterly [4]. The episodic migraine HALO trial also used 225 mg monthly [2]. A phase 2b trial of ubrogepant (a different CGRP drug) tested doses from 1 mg to 100 mg, showing a clear dose-response [3]. But for fremanezumab, the retrieved records do not include a published dose-ranging study that explains why 225 mg was chosen over, say, 175 mg. The 225 mg number appears in clinical trials as the fixed monthly dose, and a 2024 prospective study used it as the standard fremanezumab dose [6]. A pediatric phase 1 study tested 75 mg in children weighing 17-45 kg, and modeling suggested 120 mg monthly for those under 45 kg [1]. That is the closest thing to a weight-based adjustment in the records.
The evidence does not show what lower doses (like 175 mg) were tested in adults or why they were rejected. The manufacturer, Teva, funded the pivotal trials [4]. The systematic review noted that trials had short follow-up and homogeneous populations [5]. Without a published dose-finding study, the 225 mg dose appears to be a round number chosen from a limited set of tested regimens, not the result of a granular optimization. The data the asker wants — a full dose-response curve with intermediate doses — is not in these records.
My call: the 225 mg dose is what the manufacturer tested and the FDA approved, but the evidence for why it is the optimal dose rather than a lower one is absent from this retrieval. Confidence: low for the dose-optimization question.
Sources used 6
-
CGRP in Childhood and Adolescence Migraine: (Patho)physiological and Clinical Aspects
A concise review of CGRP biology in childhood and adolescence migraine, noting mature CGRP pathways in youths, observed biomarker changes, and the early, limited pediatric evidence for CGRP-targeted therapies alongside ongoing trials.
DOI: 10.1007/s11916-022-01047-5 -
Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine
Fremanezumab, a CGRP-targeting monoclonal antibody, reduces monthly migraine days and related disability across chronic and episodic migraine, including difficult-to-treat cases, with durable benefits seen in long-term use and in patients who previously failed multiple preventiv…
DOI: 10.1042/etls20200018 -
Migraine treatment: the doors for the future are open, but with caution and prudence
A narrative review summarizing CGRP-targeted migraine therapies (CGRP receptor antagonists and anti-CGRP monoclonal antibodies), detailing their mechanisms, pivotal randomized trials, efficacy on migraine days, safety/tolerability, long-term considerations, and cautious optimism…
DOI: 10.1590/0004-282X20190004 -
Fremanezumab for the Preventive Treatment of Chronic Migraine
This phase 3 trial demonstrated that fremanezumab, a humanized monoclonal antibody targeting CGRP, significantly reduces the frequency of headache days in patients with chronic migraine compared to placebo.
DOI: 10.1056/NEJMoa1709038 -
Efficacy and Safety of Fremanezumab in the Preventive Treatment of Migraine: A Systematic Review of Randomized Clinical Trials
This systematic review found that fremanezumab significantly reduced migraine frequency and produced clinically meaningful response rates, with a low rate of treatment-unrelated serious adverse events, though trials had short follow-up and homogeneous populations.
DOI: 10.46979/rbn.v61i4.69673 -
Evaluation of the efficacy of preventive therapy in chronic migraine with or without medication overuse headache: data from a prospective study
Guideline-based preventive therapy reduces monthly headache days in chronic migraine with and without medication overuse headache (MOH), with detoxification potentially diminishing differences between groups and anti-CGRP monoclonal antibodies or botulinum toxin yielding notable…
DOI: 10.14412/2074-2711-2024-1s-59-65